Laboratory of Molecular Neuro-Oncology, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Otfried-Müller-Strasse 27, 72076 Tübingen, Germany.
Carcinogenesis. 2010 Mar;31(3):411-8. doi: 10.1093/carcin/bgp319. Epub 2009 Dec 16.
The identification of genes involved in carcinogenesis and tumor progression is of great interest since these genes might be feasible as candidates for new tumor-targeted therapy strategies. Chimeric tumor suppressor-1 (CTS-1), an artificial synthetic variant of p53, resists common p53 inactivation and could therefore be defined as a dominant-positive p53 variant. Overexpression of CTS-1 induces caspase-independent cell death. We used whole-genome microarray expression analysis in a parental (229(P)) and a CTS-1-resistant glioma cell line (229(Res)) to analyze alterations in gene expression in Ad-CTS-1-infected and in uninfected parental and resistant cells. In total, 700 genes were differentially expressed in infected and 313 genes in uninfected 229(Res) versus 229(P) cells. Ingenuity Pathway Analysis determined a variety of differentially expressed genes in Ad-CTS-1-infected cells that were members of intracellular networks with central tumor-involved players such as nuclear factor-kappaB (NFkappaB), protein kinase B/AKT or transforming growth factor-beta. Here we focused on the function of NFkappaB in Ad-CTS-1-mediated cell death in glioma. NFkappaB was activated in Ad-CTS-1-infected 229(P) but not 229(Res) cells. NFkappaB activation was accompanied by the induction of cell death in parental cells. Inhibition of NFkappaB activity by expression of an IkappaB super repressor or upregulation of the NFkappaB-linked gene Bex protected parental cells to Ad-CTS-1-induced cell death, whereas knockdown of Bex sensitized both parental and resistant cells. Taken together, these data suggest that activation of the normally antiapoptotic protein NFkappaB does not always necessarily protect cells from apoptosis but, in the glioma cell lines tested so far, and in an environment where p53 is constitutively active, also leads to the induction of cell death.
鉴定与致癌和肿瘤进展相关的基因非常重要,因为这些基因可能成为新的肿瘤靶向治疗策略的候选物。嵌合肿瘤抑制因子-1(CTS-1)是 p53 的人工合成变体,抵抗常见的 p53 失活,因此可以定义为显性阳性 p53 变体。CTS-1 的过表达诱导 caspase 非依赖性细胞死亡。我们使用全基因组微阵列表达分析在亲本(229(P))和 CTS-1 抗性神经胶质瘤细胞系(229(Res))中分析 Ad-CTS-1 感染和未感染亲本和抗性细胞中基因表达的变化。总共,700 个基因在感染的细胞中差异表达,而在未感染的 229(Res)与 229(P)细胞中,有 313 个基因差异表达。Ingenuity 通路分析确定了 Ad-CTS-1 感染的细胞中多种差异表达的基因,这些基因是具有核心肿瘤参与因子(如核因子-κB(NFkappaB)、蛋白激酶 B/AKT 或转化生长因子-β)的细胞内网络的成员。在这里,我们重点关注 NFkappaB 在 Ad-CTS-1 介导的神经胶质瘤细胞死亡中的作用。NFkappaB 在 Ad-CTS-1 感染的 229(P)细胞中被激活,但在 229(Res)细胞中未被激活。NFkappaB 激活伴随着亲本细胞中细胞死亡的诱导。通过表达 IkappaB 超级抑制剂或上调 NFkappaB 相关基因 Bex 抑制 NFkappaB 活性可保护亲本细胞免受 Ad-CTS-1 诱导的细胞死亡,而 Bex 的敲低则使亲本细胞和抗性细胞都敏感。总之,这些数据表明,通常抗凋亡蛋白 NFkappaB 的激活并不总是能使细胞免受凋亡,但在迄今为止测试的神经胶质瘤细胞系中,以及在 p53 持续激活的环境中,也会导致细胞死亡的诱导。